Cargando…

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia

Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare hematologic neoplasms characterized by leukocytosis and a hypercellular bone marrow. Although recurrent mutations in the colony-stimulating factor 3 receptor (CSF3R) are frequently observed in patients with (CN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khanna, Vishesh, Pierce, Scott T, Dao, Kim-Hien T, Tognon, Cristina E, Hunt, David E, Junio, Brian, Tyner, Jeffrey W, Druker, Brian J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725740/ https://www.ncbi.nlm.nih.gov/pubmed/26870618 http://dx.doi.org/10.7759/cureus.414

Ejemplares similares

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia
por: Dao, Kim-Hien T., et al.
Publicado: (2014)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

MEK1 is required for the development of NRAS-driven leukemia
por: Nowacka, Joanna D., et al.
Publicado: (2016)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
por: Simon, Sonja C. S., et al.
Publicado: (2023)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia
por: Watanabe-Smith, Kevin, et al.
Publicado: (2016)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
por: Wang, Shujuan, et al.
Publicado: (2020)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

Comprehensive molecular characterization of a rare case of Philadelphia chromosome–positive acute myeloid leukemia
por: Rosenberg, Mara W., et al.
Publicado: (2022)

The PI3K/Akt1 pathway enhances steady-state levels of FANCL
por: Dao, Kim-Hien T., et al.
Publicado: (2013)

Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis
por: Guarnera, Luca, et al.
Publicado: (2022)

Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
por: Ramdohr, Florian, et al.
Publicado: (2022)

Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
por: Elsayed, Marwa, et al.
Publicado: (2022)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation
por: Brendel, Cornelia, et al.
Publicado: (2015)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Treatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition
por: Chowers, Guy, et al.
Publicado: (2022)

Two myeloid leukemia cases with rare FLT3 fusions
por: Zhang, Haijiao, et al.
Publicado: (2018)

Functional characterization of two rare BCR–FGFR1(+) leukemias
por: Barnes, Evan J., et al.
Publicado: (2020)

Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia
por: Romine, Kyle A., et al.
Publicado: (2023)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia
por: Kurtz, Stephen E., et al.
Publicado: (2022)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
por: Vu, Ha Linh, et al.
Publicado: (2015)

RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia
por: Ren, Jian-Gang, et al.
Publicado: (2023)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Murine Models of Acute Myeloid Leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2022)

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
por: Rice, William G., et al.
Publicado: (2022)

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
por: Lamble, Adam J., et al.
Publicado: (2020)

Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent
por: Leonard, Jessica T., et al.
Publicado: (2016)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
por: Vidal-Cruchez, Olivia, et al.
Publicado: (2023)

Corrigendum: Murine models of acute myeloid leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2023)

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling
por: Bright, Michael D., et al.
Publicado: (2018)

Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
por: Giallongo, Cesarina, et al.
Publicado: (2015)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Smith, Brittany M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rv51fcgkmlkcdsvc7ubk5i0368